// App-Quantinova.ai

381 : Circulating tumor cells (CTC) but not circulating endothelial cells (CEC) are independent prognostic factors in neoadjuvant chemotherapy combined with bevacizumab in HER2 negative inflammatory breast cancer (IBC) in multicentre phase II trial BEVERLY1

Researchers

Presenter

  • Jean-Yves Pierga

Principal Investigators

  • Francois-Clement Bidard

  • Aurelie Autret

  • Jerome Lemonnier

  • Francois Bertucci

  • Patrice Viens

  • Fabrice Andre

  • Thierry Petit

  • Florence Dalenc

  • Christel Levy

  • William Jacot

  • Jacques Bonneterre

  • Jean-Marc Ferrero

  • Pierre Kerbrat

Medical Centers

  • IRCM, Montpellier, France

  • Centre Antoine-Lacassagne, Nice, France

  • Institut Paoli-Calmettes, Marseille, France

  • Institut Paoli-Calmettes, Marseille, France

  • Centre Francois Baclesse, Caen, France

  • Institut Curie, Paris Cedex, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 105 Antigen

  • Epithelial Cell Adhesion Molecule

  • Human epidermal growth factor receptor 2

  • Melanoma Cell Adhesion Molecule

Drug/Treatment

  • Bevacizumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved